Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

PubWeight™: 2.06^‹?› | Rank: Top 2%

🔗 View Article (PMID 26562292)

Published in JAMA Oncol on February 01, 2016

Authors

Mark Clemons¹, Nathaniel Bouganim², Stephanie Smith³, Sasha Mazzarello³, Lisa Vandermeer³, Roanne Segal², Susan Dent², Stan Gertler², Xinni Song², Paul Wheatley-Price², George Dranitsaris²

Author Affiliations

1: Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada2Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
2: Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
3: Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Associated clinical trials:

Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. (ER11-02) | NCT01913990

Articles citing this ↘

Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front Pharmacol (2017) 0.79

Patient risk factors versus physician guidelines for anti-emetics. Lancet Oncol (2015) 0.75

Can Patient Risk Factors Outperform Antiemetic Guidelines?: Choosing Wisely. JAMA Oncol (2016) 0.75

A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Support Care Cancer (2017) 0.75